Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company focused on designing and developing DARPin therapeutics, a proprietary protein-drug platform. The company is headquartered in Switzerland with a U.S. subsidiary in Massachusetts, and its pipeline spans oncology, radiopharmaceuticals, and virology programs developed both internally and with partners.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueEngineered protein drugs built on the DARPin platform for therapeutic use.
Cancer-focused therapeutic candidates, including immune-engaging and radiopharma assets.
Targeted alpha therapy programs based on 212Pb and related constructs.
Multispecific biologics designed to redirect immune cells against tumors.
Discovered or co-developed programs with pharmaceutical and academic partners.
Customers
Molecular Partners does not sell commercial medicines; its direct counterparties are pharmaceutical partners, academic collaborators, and clinical investigators that participate in discovery, co-development, and trial execution. Its eventual end customers are patients and treating physicians in oncology and other serious-disease settings, where differentiated biologics are intended to address unmet medical needs. Partnership structures also mean that milestone-paying pharma collaborators are a key economic customer segment. Clinical sites and research institutions are important users of its investigational assets during development.
Buy rights, co-development access, or partner with Molecular Partners on specific pipeline assets and platform programs.
Collaborate on early-stage discovery and translational programs that extend the DARPin platform.
Hospitals, investigators, and sites that evaluate investigational products in Phase 1/2 studies.
End beneficiaries of cancer and other serious-disease therapies once products are approved.
Strategy
The company’s strategy centers on advancing DARPin-based medicines through internal R&D and external collaborations, with a concentration on oncology and adjacent serious-disease areas. It is building multiple modalities on the same platform, including targeted radiopharmaceuticals and multispecific immune cell engagers, to broaden the addressable pipeline and increase the chance of partnerable or internally owned assets reaching the clinic.
Clinical data are the main value inflection points for a biotech without marketed products.
A broader platform can create more shots on goal and diversify technical risk.
Partner capital and expertise reduce funding burden and expand development optionality.
Geography
Molecular Partners is organized around a Swiss parent company with a U.S. subsidiary and offices in both Zurich and Concord, Massachusetts. The business is therefore split between European headquarters functions and U.S.-based corporate and development activities, while its product development and partnering are global in scope. The provided reports do not disclose revenue by country, which is consistent with the company’s pre-commercial stage. Geography matters mainly through where research staff, clinical operations, and partner relationships are located rather than through sales concentration.
Risks
As a clinical-stage biotech, Molecular Partners faces high clinical-development risk: individual programs can fail in preclinical work or in human studies, and success depends on data quality, trial design, and regulatory outcomes. The business also depends on external financing and partnership execution because it has no commercial product revenue, while platform-specific technical risk remains significant if DARPin candidates do not translate into durable therapeutic benefit.
- Clinical development failureImpact: CriticalLikelihood: High
The pipeline is in preclinical and early clinical stages, where attrition is high and efficacy/safety can disappoint.
Exposure - Funding dependenceImpact: HighLikelihood: High
With no product sales, ongoing R&D requires cash from financing, partnerships, or future capital raises.
Exposure: Group-wide operating funding
- Platform translation riskImpact: HighLikelihood: Medium
Success in one DARPin modality does not guarantee success in others such as radiopharma or immune engagers.
Exposure: Technology platform
- Partner execution riskImpact: MediumLikelihood: Medium
Co-development timelines and economics depend on counterparties’ commitment and priorities.
Exposure: Orano Med collaboration and other partnered programs
Accounting
Judgemental itemsClinical and preclinical spending is expensed as incurred, so trial timing directly changes reported operating loss.
Impact: Can create large quarter-to-quarter swings in reported results
Stock compensation is material for a biotech and affects both SG&A and R&D presentation.
Impact: Non-cash expense can distort underlying cash burn analysis
The company disclosed remeasurement of net pension liabilities, which can move equity and comprehensive income.
Impact: Adds volatility to OCI and shareholders' equity
Swiss headquarters and U.S. operations create translation effects between CHF and USD.
Impact: Can affect equity and comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Moleculin Biotech, Inc.
MBRX · Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Monte Rosa Therapeutics, Inc.
GLUE · Biological Products, (No Diagnostic Substances)
Monte Rosa Therapeutics is a biotechnology company developing small-molecule molecular glue degraders (MGDs) that use the cell’s own protein-destruction…
C4 Therapeutics, Inc.
CCCC · Biological Products, (No Diagnostic Substances)
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Last updated: 28/09/2026